Refine by
Antigen Protein Articles & Analysis
22 news found
The platform covers both linear and conformational epitope analysis and includes the following core services: l Binding Activity Confirmation: ELISA or Western blot assays to verify the interaction between the submitted antibody and antigen. l Glycosylation Analysis (Optional): Comparing antibody binding to glycosylated versus deglycosylated forms of the ...
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the expansion of its Hepatitis B research portfolio with a comprehensive range of sensitive and specific Hepatitis B Virus Surface Antigen L-proteins. ...
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, is excited to announce the launch of its new line of H5N1 Antibodies and Antigens to support cutting-edge research on this highly pathogenic influenza A virus subtype. ...
The company's portfolio includes immune checkpoint proteins, CAR-T cell targets, CD antigens, fluorescent-labeled recombinant proteins, PROTAC targets, and more. ...
” The Targeted Radionuclide Therapy with ITM-31 targets a specific protein (antigen) called CA XII, which is highly expressed on the cell surface of glioblastoma cells, but not found on healthy glial cells, a specific subpopulation of brain cells. ...
Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this platform was used to express a malaria protein antigen that can be delivered intranasally and later boosted with a simple oral booster. ...
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of IPD and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic ...
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made ...
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made ...
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made ...
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of IPD and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic ...
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of IPD and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic ...
As a first priority, Abera will conduct studies within the concept of therapeutic vaccines and apply the company’s platform BERA to present tumor antigens (i.e. proteins that are unique to tumors and are not found in healthy cells) to the human body to effectively trigger the immune system to attack tumors. It is a challenge to create an immune response to ...
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through ...
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of IPD. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, ...
The latest vaccine platform makes it possible to produce single, or multiple, antigens in so-called protein bodies. Antigens are the pathogen-specific components of vaccines that elicit immune responses. Protein bodies are nano-sized protein particles. The company is now entering into a partnership with an ...
ASHI 2021 -- At the annual meeting for the American Society for Histocompatibility and Immunogenetics (ASHI) this week, Thermo Fisher Scientific announced two new additions to its transplant diagnostics portfolio. These new products will enable transplant laboratories to better characterize samples and bring speed and confidence to the transplant laboratory. More than 100,000 adults are now on a ...
The authors identified ways to improve the ability to express complex proteins at the surface of bacterial cells using in Abera’s display technology. ...
It entails technology that allows the efficient production of disease-specific antigens in so-called protein bodies, nanosized protein particles that can be administered to the body as vaccines. ...
The goal of any vaccine is to generate immunity to pathogens, in order to reduce the spread of infectious diseases. A vaccine antigen (a foreign substance, usually a protein, that induces an immune response) is introduced into the body (most often via an injection), with the intention of stimulating the production of antibodies helpful in fighting off future ...